Diadema Partners LP Intellia Therapeutics, Inc. Transaction History
Diadema Partners LP
- $391 Billion
- Q3 2025
A detailed history of Diadema Partners LP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 470,200 shares of NTLA stock, worth $4.09 Million. This represents 2.08% of its overall portfolio holdings.
Number of Shares
470,200Holding current value
$4.09 Million% of portfolio
2.08%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding NTLA
# of Institutions
343Shares Held
103MCall Options Held
3.16MPut Options Held
1.56M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.9MShares$104 Million1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$96.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$83.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY6.02MShares$52.4 Million0.01% of portfolio
-
Contrarius Group Holdings LTD Hamilton, D05.89MShares$51.2 Million4.6% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $661M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...